Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07592689 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
A Phase 3 study, sponsored by Definium Therapeutics US.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
NCT07592689: Recruiting Phase 3 study, sponsored by Definium Therapeutics US.
NCT07592689 is a Phase 3 study that is actively recruiting participants, run by Definium Therapeutics US. The registered enrollment target is 165 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07592689, a Phase 3 study, is actively recruiting participants, sponsored by Definium Therapeutics US.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
Study Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
Primary Outcome
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.
Interventions
- OTHER Placebo
- DRUG DT120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2026-05-10 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
What NCT07592689 shows while recruiting
NCT07592689 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07592689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07592689 about?
NCT07592689 is a clinical study titled "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)". A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend
What is the current status of trial NCT07592689?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2026-05-10. Estimated completion is 2028-06.
What interventions are being tested in trial NCT07592689?
The interventions under investigation include: Placebo (OTHER), DT120 (DRUG).
Who is sponsoring clinical trial NCT07592689?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07592689's enrollment target sits among peer trials
165 1465th of 2000 higher than 531 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI